Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(16 sites)
United States
The University of Louisville, James Graham Brown Cancer Center ( Site 0009), Louisville, Kentucky Memorial Sloan Kettering Cancer Center ( Site 0003), New York, New York Houston Methodist Hospital ( Site 0010), Houston, Texas START Mountain Region ( Site 0008), West Valley City, Utah University of Virginia Health System ( Site 0011), Charlottesville, Virginia